Have a feature idea you'd love to see implemented?
Let us know!
UTHR UNITED THERAPEUTICS Corp
Price (delayed)
$350.19
Market cap
$15.58B
P/E Ratio
15.17
Dividend/share
N/A
EPS
$23.09
Enterprise value
$14.72B
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and
Highlights
The debt has contracted by 38% YoY and by 17% from the previous quarter
The company's revenue rose by 24% YoY and by 4.7% QoQ
The quick ratio has dropped by 51% year-on-year but it has increased by 12% since the previous quarter
The stock's P/E is 31% above its last 4 quarters average of 11.6 and 10% above its 5-year quarterly average of 13.8
Key stats
What are the main financial stats of UTHR
Market
Valuations
Earnings
Shares outstanding
44.49M
Market cap
$15.58B
Enterprise value
$14.72B
Price to earnings (P/E)
15.17
Price to book (P/B)
2.73
Price to sales (P/S)
5.94
EV/EBIT
10.11
EV/EBITDA
9.7
EV/Sales
5.63
Revenue
$2.62B
EBIT
$1.46B
EBITDA
$1.52B
Free cash flow
$877.9M
Per share
Balance sheet
Liquidity
EPS
$23.09
Free cash flow per share
$19.77
Book value per share
$128.44
Revenue per share
$58.93
TBVPS
$148.83
Total assets
$6.72B
Total liabilities
$1.03B
Debt
$500M
Equity
$5.7B
Working capital
$2.79B
Debt to equity
0.09
Current ratio
4.35
Quick ratio
3.92
Net debt/EBITDA
-0.56
Margins
Efficiency
Dividend
EBITDA margin
58%
Gross margin
88.8%
Net margin
40.9%
Operating margin
48.3%
Return on assets
15.6%
Return on equity
18.8%
Return on invested capital
27.2%
Return on capital employed
24.7%
Return on sales
55.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UTHR stock price
How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-0.68%
1 week
-6.07%
1 month
-2.15%
1 year
54.11%
YTD
59.26%
QTD
-2.28%
Financial performance
How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.62B
Gross profit
$2.32B
Operating income
$1.26B
Net income
$1.07B
Gross margin
88.8%
Net margin
40.9%
The company's revenue rose by 24% YoY and by 4.7% QoQ
UNITED THERAPEUTICS's net income has increased by 23% YoY
The company's gross profit rose by 22% YoY and by 4.7% QoQ
The operating income has grown by 16% YoY
Growth
What is UNITED THERAPEUTICS's growth rate over time
Valuation
What is UNITED THERAPEUTICS stock price valuation
P/E
15.17
P/B
2.73
P/S
5.94
EV/EBIT
10.11
EV/EBITDA
9.7
EV/Sales
5.63
The stock's P/E is 31% above its last 4 quarters average of 11.6 and 10% above its 5-year quarterly average of 13.8
The company's EPS rose by 23% YoY and by 3.3% QoQ
UTHR's price to book (P/B) is 37% higher than its 5-year quarterly average of 2.0 and 37% higher than its last 4 quarters average of 2.0
The equity has increased by 7% since the previous quarter and by 5% year-on-year
The stock's P/S is 26% above its 5-year quarterly average of 4.7 and 26% above its last 4 quarters average of 4.7
The company's revenue rose by 24% YoY and by 4.7% QoQ
Efficiency
How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 30% YoY and by 6% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 11% YoY
The ROE has grown by 7% YoY
The company's return on sales fell by 3.3% QoQ
Dividends
What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UTHR.
Financial health
How did UNITED THERAPEUTICS financials performed over time
The quick ratio has dropped by 51% year-on-year but it has increased by 12% since the previous quarter
The current ratio has contracted by 50% YoY but it has grown by 15% from the previous quarter
The debt is 91% less than the equity
UNITED THERAPEUTICS's debt to equity has decreased by 40% YoY and by 18% QoQ
The debt has contracted by 38% YoY and by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.